, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on July 11, dosing commenced of the first patients enrolled in the Company’s Phase 3 registration clinical trials of RhopressaTM, a
dosing הגייה עם משמעויות, מילים נרדפות, הפכים, תרגומים, משפטים ועוד